St Renatus Drug Patent Portfolio
St Renatus owns 1 orange book drug protected by 3 US patents Given below is the list of St Renatus's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8580282 | Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration | 02 Apr, 2030 | Active |
| US9308191 | Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration | 02 Apr, 2030 | Active |
| US6413499 | Methods and kits for maxillary dental anesthesia by means of a nasal deliverable anesthetic | 20 Mar, 2020 | Expired |
Latest Legal Activities on St Renatus's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of St Renatus.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 20 May, 2024 | US9308191 |
|
Maintenance Fee Reminder Mailed
Critical
| 04 Dec, 2023 | US9308191 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 28 Apr, 2021 | US8580282 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 27 Sep, 2019 | US9308191 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 06 Apr, 2018 | US9308191 |
|
Email Notification
Critical
| 06 Apr, 2018 | US9308191 |
|
Email Notification
Critical
| 05 Apr, 2018 | US8580282 |
|
Correspondence Address Change
Critical
| 05 Apr, 2018 | US9308191 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 05 Apr, 2018 | US8580282 |
|
Correspondence Address Change
Critical
| 04 Apr, 2018 | US8580282 |
|
Correspondence Address Change
Critical
| 08 Nov, 2017 | US9308191 |
|
Correspondence Address Change
Critical
| 08 Nov, 2017 | US8580282 |
|
Patent Term Extension (156) Dismissed
Critical
| 30 Aug, 2017 | US8580282 |
|
Patent Term Extension (156) Dismissed
Critical
| 30 Aug, 2017 | US9308191 |
| Letter from FDA or Dept of Agriculture re PTE application | 12 Jul, 2017 | US8580282 |
St Renatus's Family Patents
St Renatus drugs have patent protection in a total of 16 countries. It's US patent count contributes only to 31.2% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
St Renatus Drug List
Given below is the complete list of St Renatus's drugs and the patents protecting them.
1. Kovanaze
Kovanaze is protected by 3 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8580282 | Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration |
02 Apr, 2030
(5 years from now)
| Active |
| US9308191 | Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration |
02 Apr, 2030
(5 years from now)
| Active |
| US6413499 | Methods and kits for maxillary dental anesthesia by means of a nasal deliverable anesthetic |
20 Mar, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kovanaze's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List